PTC Therapeutics, Inc.

Historical 13F Holders

Symbol
PTCT
CUSIP
69366J200
All holders as of
Q2 2026
Type
Equity
Class
COM
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 69366J200 since 12/18/2024, newest first.

Filer % of Class Filed
Janus Henderson Group PLC 13G/A Amendment 1 8.7% 5/15/2026
Event 3/31/2026
Toronto Dominion Bank 13G/A Amendment 1 3.7% 5/15/2026
Event 3/31/2026
Vanguard Capital Management LLC 13G 5.2% 4/30/2026
Event 3/31/2026
Vanguard Portfolio Management LLC 13G 5.9% 4/29/2026
Event 3/31/2026
Vanguard Group Inc 13G/A Amendment 11 0% 3/27/2026
Event 3/13/2026
Janus Henderson Group PLC 13G 6.0% 2/17/2026
Event 12/31/2025
Toronto Dominion Bank 13G 5.2% 2/13/2026
Event 12/31/2025
Wellington Management Group LLP 13G/A Amendment 7
4.8% 2/10/2026
Event 12/31/2025
State Street Corp 13G 5.2% 2/9/2026
Event 12/31/2025
BlackRock, Inc. 13G/A Amendment 12 14.8% 12/4/2025
Event 11/30/2025
Vanguard Group Inc 13G/A Amendment 10 10.4% 10/30/2025
Event 9/30/2025
Armistice Capital, LLC 13G/A Amendment 3
6.9% 5/15/2025
Event 3/31/2025
BlackRock, Inc. 13G/A Amendment 11 8.0% 4/17/2025
Event 3/31/2025
Camber Capital Management LP 13G/A Amendment 1
4.2% 2/14/2025
Event 12/31/2024
Armistice Capital, LLC 13G/A Amendment 2
8.3% 2/14/2025
Event 12/31/2024
Wellington Management Group LLP 13G/A Amendment 6
6.2% 2/10/2025
Event 12/31/2024

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2026 Q3 8 22.5 k $1.46 M
2026 Q2 397 107 M $8.28 B
2026 Q1 367 95.6 M $6.51 B
2025 Q4 370 92.8 M $7.04 B
2025 Q3 311 83.2 M $5.10 B
2025 Q2 301 85.5 M $4.18 B
2025 Q1 273 78.9 M $4.03 B
2024 Q4 252 77.8 M $3.51 B
2024 Q3 217 79.4 M $2.95 B
2024 Q2 212 82.0 M $2.51 B
2024 Q1 202 90.0 M $2.62 B
2023 Q4 187 87.1 M $2.40 B
2023 Q3 194 81.7 M $1.84 B
2023 Q2 218 81.1 M $3.30 B
2023 Q1 222 78.5 M $3.81 B
2022 Q4 220 80.5 M $3.08 B
2022 Q3 227 78.5 M $3.94 B
2022 Q2 192 74.1 M $2.97 B
2022 Q1 191 74.5 M $2.77 B
2021 Q4 190 75.5 M $3.01 B
2021 Q3 190 74.6 M $2.78 B
2021 Q2 196 74.2 M $3.14 B
2021 Q1 219 74.1 M $3.52 B
2020 Q4 228 73.3 M $4.47 B
2020 Q3 217 71.5 M $3.34 B
2020 Q2 227 69.2 M $3.49 B
2020 Q1 223 64.3 M $2.87 B
2019 Q4 234 62.0 M $2.98 B
2019 Q3 211 63.1 M $2.13 B
2019 Q2 202 58.4 M $2.63 B
2019 Q1 197 59.3 M $2.23 B
2018 Q4 186 49.3 M $1.69 B
2018 Q3 204 48.1 M $2.26 B
2018 Q2 189 43.1 M $1.45 B
2018 Q1 169 43.2 M $1.17 B
2017 Q4 144 38.1 M $636 M
2017 Q3 161 35.7 M $715 M
2017 Q2 131 33.5 M $615 M
2017 Q1 139 31.6 M $311 M
2016 Q4 143 29.0 M $316 M
2016 Q3 130 29.2 M $409 M
2016 Q2 128 30.0 M $212 M
2016 Q1 129 29.4 M $190 M
2015 Q4 171 36.4 M $1.18 B
2015 Q3 195 34.0 M $920 M
2015 Q2 180 32.6 M $1.57 B
2015 Q1 178 31.5 M $1.92 B
2014 Q4 137 28.4 M $1.47 B
2014 Q3 100 24.4 M $1.07 B
2014 Q2 85 23.1 M $604 M
2014 Q1 65 23.0 M $600 M